CareDx (CDNA) “announced the launch of VANTx(TM), an AI-powered, cloud-native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real-world evidence development. VANTx is designed for secure, scalable cohort analysis across longitudinal patient timelines that enables the evaluation of treatment trends, patient outcomes, and practice patterns. The platform is intended to support clinicians, transplant programs, and pharma partners in testing hypotheses to generate actionable findings for treatment protocol development, investigator-initiated studies, and clinical trial design.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CareDx: Strong Growth, Discounted Valuation, and Emerging Oncology Optionality Support Buy Rating
- CareDx price target raised to $26 from $25 at BTIG
- CareDx: Conservative Revenue Upside Offset by Weaker Margins and Coverage Uncertainty Justifying Hold Rating
- CareDx CFO Nathan Smith steps down, COO Keith Kennedy to succeed
- CareDx Names New CFO Amid Strong Q4 2025 Results